Home > Quotes > SGEN

Seattle Genetics, Inc. Common Stock Quote & Summary Data

Get SGEN Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading SGEN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Seattle Genetics, Inc. Common Stock Intraday Chart

News for SGEN

Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 37.49 $ 52.3299
Low $ 35.17 $ 26.02

The current last sale of $35.48 is 36.36% Higher thanthe 52 week low.

P/E Ratio

Company Description (as filed with the SEC)

Seattle Genetics is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer. Our marketed product ADCETRIS®, or brentuximab vedotin, is now approved by the United States Food and Drug Administration, or FDA, for three indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma, or sALCL. ADCETRIS is commercially available in more than 60 countries around the world, including in the United States, Canada, members of the European Union and Japan. We are collaborating with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis. Under this collaboration, Seattle Genetics retains commercial rights for ADCETRIS in the United States and its territories and in Canada, and Takeda has commercial rights in the rest of the world.  ... More ...  

Risk Grade

Where does SGEN fit in the risk graph?

Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?